Mast Therapeutics (NASDAQ:SVRA) was downgraded by equities researchers at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Tuesday, January 9th.
A number of other brokerages have also recently commented on SVRA. JMP Securities initiated coverage on shares of Mast Therapeutics in a research report on Monday, September 11th. They issued an “outperform” rating and a $20.00 target price on the stock. Roth Capital decreased their price objective on shares of Mast Therapeutics from $40.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, October 31st. Canaccord Genuity boosted their price target on shares of Mast Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, October 30th. ValuEngine cut shares of Mast Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, Zacks Investment Research lowered shares of Mast Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, November 23rd. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $23.58.
Shares of Mast Therapeutics (NASDAQ:SVRA) opened at $11.45 on Tuesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 9.15. Mast Therapeutics has a one year low of $4.60 and a one year high of $17.19. The company has a market cap of $349.23, a PE ratio of -3.41 and a beta of -0.26.
Mast Therapeutics (NASDAQ:SVRA) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.12. equities research analysts forecast that Mast Therapeutics will post -1.64 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Mast Therapeutics (SVRA) Downgraded by BidaskClub to Buy” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/03/bidaskclub-downgrades-mast-therapeutics-svra-to-buy.html.
Mast Therapeutics Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Mast Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.